MarginsXMarginsX
Home › Markets › Health Care › ONC

BeOne Medicines Ltd. (ONC)

ONC trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$411.29
-1.26% on the day
Market cap
$47.0B
Large cap
Revenue · 2025
$5.3B
+40.2% on 2024
Net income · 2025
$286.9M
5.4% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1651308/000162828026011946/0001628280-26-011946-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerONC on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryCayman Islands
IPO year2016
SEC CIK0001651308
SEC industry codePharmaceutical Preparations

Financials · 2025

LineValue
Revenue$5.3B
Net income$286.9M
Operating income$447.1M
Net margin5.4%
Operating margin8.4%
Revenue growth+40.2%
Cash$4.5B
Total assets$8.2B
P/E (computed)163.7×
P/S (computed)8.8×

Warning signs

Cash runway
Cash-flow positive
$5.8B cash at September 30, 2026
Share count, 1 year
+3.2%
2025-11-01 to 2026-10-30 · +9.2% over 3 years
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
-$372.4M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$5.8B cash; operating cash flow $397.6M a quarter.Report 2026-09-30
Shares outstanding114,226,079 (2026-10-30); 110,657,943 a year earlier; 104,576,740 three years earlier.Cover page 2026-10-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months2 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-05-06
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-03-12
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $372.4M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$1.9B$384.7M$508.7M$5.8B$866.2M$6.6B10-Q 2026-11-05
Q2 2026
2026-06-30
$1.7B$237.0M$462.8M$5.1B$859.9M$6.1B10-Q 2026-08-05
Q1 2026
2026-03-31
$1.5B$227.4M$201.3M$4.8B$852.2M$5.7B10-Q 2026-05-06
Q4 2025
2025-12-31
$1.5B$66.5M$417.3M$4.5B$845.4M$5.3B10-K 2026-02-26
Q3 2025
2025-09-30
$1.4B$124.8M$402.6M$4.0B$1.6B$5.0B10-Q 2026-11-05
Q2 2025
2025-06-30
$1.3B$94.3M$263.6M$2.8B$954.5M$4.6B10-Q 2026-08-05
Q1 2025
2025-03-31
$1.1B$1.3M$44.1M$2.5B$923.6M$4.2B10-Q 2026-05-06
Q4 2024
2024-12-31
$1.1B-$151.9M$75.2M$2.6B$1.9B$3.8B10-K 2026-02-26

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-3ASR2026-05-06
Latest annual report10-K2026-02-26
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-05
Latest proxyDEFA14A2026-04-28

Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+2.4%
1 month+19.3%
3 months+17.0%
Year to date+37.1%
1 year+13.1%
From 52-week high-1.8%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
TEVATeva Pharmaceutical Industries Limited$42.57-4.34%$49.7B
RPRXRoyalty Pharma plc Class A Ordinary Shares$68.53-1.13%$39.3B
ZTSZoetis Inc.$84.39+0.68%$34.3B
TAKTakeda Pharmaceutical Company Limited$21.59+0.75%$68.2B
GMABGenmab A/S ADS$51.57+0.39%$32.2B
ROIVRoivant Sciences Ltd. Common Shares$38.61-2.33%$28.0B
INSMInsmed Incorporated$122.88+1.42%$27.0B
UTHRUnited Therapeutics Corporation$587.88-0.56%$25.0B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier